Nomura downgraded Dr. Reddy’s (RDY) to Neutral from Buy with a INR 1,500 price target The firm thinks the Street is concerned about higher contribution from generic Revlimid that could start declining in fiscal 2026, saying Dr. Reddy’s overheads have increased significantly in the recent past. The company’s overhead spends remain high and revenues from new initiatives have not fully played out, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio